1.
Adv NPs PAs
; 1(2): 38-44, 2010 Oct.
Artigo
em Inglês
| MEDLINE
| ID: mdl-21299149
Assuntos
Glicemia/efeitos dos fármacos , Diabetes Mellitus Tipo 2/tratamento farmacológico , Inibidores da Dipeptidil Peptidase IV/uso terapêutico , Peptídeo 1 Semelhante ao Glucagon/agonistas , Incretinas/uso terapêutico , Ensaios Clínicos como Assunto/estatística & dados numéricos , Humanos , Profissionais de Enfermagem , Assistentes Médicos
2.
JAAPA
; Suppl Endocannabinoid: 11-4, 2007 Nov.
Artigo
em Inglês
| MEDLINE
| ID: mdl-18047037
3.
JAAPA
; Suppl Initiating Insulin: 3-8, 2007 Oct.
Artigo
em Inglês
| MEDLINE
| ID: mdl-18050526
RESUMO
Despite the armamentarium of oral and injectable agents available for the treatment of type 2 diabetes, there is clearly a significant gap between current recommendations for glycemic targets and the proportion of patients who can achieve and maintain glycemic control. Early diagnosis and intervention, particularly with the initiation of insulin therapy, may delay the progressive loss of pancreatic beta cells and the risk for macrovascular and microvascular complications. While there are numerous myths and misconceptions surrounding insulin therapy, physician and patient education, as well as an awareness of cultural sensitivities, can be instrumental in overcoming these barriers.